ArticleCancer discovery2021
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 56 citations in OpenAlex.
- A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.Nature biotechnology · 2025Trial
- De Novo Discovery of Nonstandard Thioisoindole-Bridged Bicyclic Peptides Targeting Traf2- and NCK-Interacting Kinase.Angewandte Chemie (International ed. in English) · 2026Article
- KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.Leukemia · 2026Article
- Integrating machine learning and single-cell sequencing to reveal the role of kinase-related genes in subtype classification and prognostic significance of lung squamous cell carcinoma.Discover oncology · 2026Article
- Subtype-specific prognostic impact of TNIK in medulloblastoma.Journal of neuro-oncology · 2026Article
- The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC-High SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- A system-wide investigation into the phosphoregulatory network of TNIK and its cellular implications.Frontiers in bioinformatics · 2026Article
- The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma.Experimental hematology & oncology · 2025Article
- MAP4K signaling pathways in cancer: roles, mechanisms and therapeutic opportunities.Experimental & molecular medicine · 2025Review
- TRAF2 and NCK interacting kinase: a novel regulator of integrin αResearch and practice in thrombosis and haemostasis · 2025Article
- Rap2a promotes cardiac fibrosis and exacerbates myocardial infarction through the TNIK/Merlin/YAP axis.Cell biology and toxicology · 2025Article
- RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer.Signal transduction and targeted therapy · 2025Article
- Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.Molecular cancer therapeutics · 2025Article
- Nf2-FAK signaling axis is critical for cranial bone ossification and regeneration.Nature communications · 2025Article
- Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.Science signaling · 2025Article
- Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches.Cancer discovery · 2025Article
- TNIK-driven regulation of ERK5 transcriptional activity in endothelial cells.Frontiers in cardiovascular medicine · 2025Article
- Functional annotation of the Hippo pathway somatic mutations in human cancers.Nature communications · 2024Article
- Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth.bioRxiv : the preprint server for biology · 2024Article
- TNIK in disease: from molecular insights to therapeutic prospects.Apoptosis : an international journal on programmed cell death · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Pedro Torres-AyusoLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland. john.brognard@nih.gov torresayusop2@nih.gov.ORCID 0000-0003-2213-9014
Elvira AnLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland.
Katherine M NyswanerLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland.
Ryan C BensenLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland.
Daniel A RittLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland.
Suzanne I SpechtLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland.
Sudipto DasProtein Characterization Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Thorkell AndressonProtein Characterization Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Raul E CachauAdvanced Biomedical Computational Science, Biomedical Informatics and Data Science, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Roger J LiangLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland.
Amy L RiesLaboratory Animal Sciences Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Christina M RobinsonLaboratory Animal Sciences Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Simone DifilippantonioLaboratory Animal Sciences Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Brad GoukerMolecular Histopathology Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Laura BasselMolecular Histopathology Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Baktiar O KarimMolecular Histopathology Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Chad J MillerDepartment of Pharmacology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-2087-6566
Benjamin E TurkDepartment of Pharmacology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-9275-4069
Deborah K MorrisonLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland.
John BrognardLaboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland. john.brognard@nih.gov torresayusop2@nih.gov.
Center for Cancer Research · USLeidos (United States) · USYale University · USFrederick National Laboratory for Cancer Research · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MOncogenic Kinases in CancerZIABC011691 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BROGNARD, JOHN · 2016 to 2025
$14.4MRole of Protein Scaffolds in RTKRas-dependent Signal TransductionZIABC011107 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MORRISON, DEBORAH · 2009 to 2025
$7.3MStructure-directed investigations into the regulation of Ste20 kinasesR01GM102262 · NIGMS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON · 2012 to 2025
$4.2MIntramural NIH HHS ZIA BC011691NCI NIH HHS 75N91019D00024NIGMS NIH HHS R01 GM102262
Abstract
Lung squamous cell carcinoma (LSCC) is the second most prevalent type of lung cancer. Despite extensive genomic characterization, no targeted therapies are approved for the treatment of LSCC. Distal amplification of the 3q chromosome is the most frequent genomic alteration in LSCC, and there is an urgent need to identify efficacious druggable targets within this amplicon. We identify the protein kinase TNIK as a therapeutic target in LSCC.
Indexed as
AnimalsAntineoplastic AgentsCarcinoma, Squamous CellCell Line, TumorEpithelial CellsGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceMolecular Targeted TherapyProtein Kinase InhibitorsProtein Serine-Threonine KinasesAntineoplastic AgentsProtein Kinase InhibitorsProtein Serine-Threonine KinasesTNIK protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.